Anand Anandkumar at Bugworks on how India could become a powerhouse of biotech research

4006 Listen ins

Our guest today is Anand Anandkumar, CEO and MD of Bugworks Research, a clinical phase drug discovery company that is attempting to develop a new class of antibiotics to tackle what's called 'antimicrobial resistance,' arising out of infectious bugs evolving to become resistant to multiple drugs. In this episode, Anand talks about the many challenges of commercialising scientific breakthroughs from India. He also talks about the opportunity for this country to become a biotech powerhouse